Real-World Effectiveness and Safety of Bempedoic Acid: Insights From the 1-Year Follow-Up Italian Cohort Data of the Milos Study

“Far too many patients across Europe still fail to reach their LDL-C targets, leaving them unnecessarily exposed to cardiovascular risk. The real-world data being presented at EAS 2026 provide critical evidence to help clinicians bridge these treatment gaps in routine practice and improve outcomes for a diverse range of patients.”

“The extensive data set we are presenting at EAS 2026 – a testament to our sustained investment in cardiovascular health – reinforces our mission to give every patient a chance to reach their treatment goals. By translating scientific innovation into practical, patient-centred care, we are ensuring that we care for every heartbeat through innovative and accessible solutions.”